FindTrial
Sign In

A study to Evaluate a new blood test (presepsin) for Early detection of serious Infections in Critically Ill Cancer Patients, compared to existing blood tests

Assessment of Presepsin For Early Diagnosis in septic Hemato Oncology ICU Patients as compared to Procalcitonin and CRP im a mixed intensive Care unit of a Tertiary Care Hospital-A Pilot Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/06/112925
Enrollment
50
Registered
2026-06-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A419- Sepsis, unspecified organism

Interventions

Intervention1: Nil: Nil

Sponsors

Medanta The Medicity
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Age More than or equal to 18 years 2)Hematology and oncology patients. admitted to ICU with suspected or confirmed infection (Sepsis III Criteria) 3)Patient or their legally acceptable representatives who voluntarily provide written informed consent

Exclusion criteria

Exclusion criteria: 1)Patients with end-stage renal disease on Dialysis. 2)Pregnant women.

Design outcomes

Primary

MeasureTime frame
SepsisTimepoint: 6 months—

Secondary

MeasureTime frame
ICU mortality and/or in-hospital mortality. Requirement of vasopressor/inotropic support. Requirement of invasive mechanical ventilation. Duration of mechanical ventilation. Length of ICU stay Time to resolution of sepsis. Antibiotic de-escalation based on clinical and biomarker improvement. Correlation of serial presepsin levels with clinical improvement and organ dysfunction Timepoint: 6 months—

Countries

India

Contacts

Public ContactDr Yatin Mehta

Medanta The Medicity

yatin.mehta@medanta.org01244141414

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026